Breaking News Instant updates and real-time market news.

CELG

Celgene

$94.70

1.44 (1.54%)

07:14
08/19/19
08/19
07:14
08/19/19
07:14

Celgene downgraded to Neutral from Buy at Mizuho

  • 03

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

CELG Celgene
$94.70

1.44 (1.54%)

05/28/19
GSCO
05/28/19
INITIATION
Target $54
GSCO
Buy
Bristol-Myers initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Bristol-Myers Squibb with a Buy rating and $54 price target. Bristol-Myers is trading at a "significant discount to the group," Flynn tells investors in a research note. The analyst says his call is based on valuation, and he sees potential for multiple expansion whether or not the Celgene (CELG) acquisition closes.
06/24/19
CANT
06/24/19
NO CHANGE
Target $100
CANT
Neutral
Celgene pushback surprising, but deal should still close, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young said she was surprised by the FTC pushback around Otezla and its overlap in psoriasis related to Celgene's (CELG) oral TYK2 program BMS-986165 in psoriasis given that the latter has not yet reported Phase 3 data. After speaking to Bristol-Myers (BMY), Young said management was also disappointed in this FTC decision, which they said was not related to current asset Orencia marketed for rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. Though timelines are delayed, she still sees "a high likelihood" that the deal closes, but potentially 4-6 months behind schedule. Young, who sees many players in Inflammation & Immunology that could leverage oral Otezla with their existing salesforce, added that Bristol may not lose much in value from this divestiture if the process is competitive. She keeps a Neutral rating and $100 price target on Celgene shares.
06/25/19
WBLR
06/25/19
NO CHANGE
WBLR
Outperform
Bristol-Myers sentiment suffered 'double hit' yesterday, says William Blair
William Blair analyst Matt Phipps said Bristol-Myers (BMY) suffered a "double hit to sentiment" yesterday with the news of both the CheckMate-459 trial failure in first-line hepatocellular carcinoma and delay of the closing of its Celgene (CELG) deal due to the required Otezla divestiture. He had previously modeled Opdivo sales in the front-line setting of over $1B and Otezla sales growing to $3B before loss of exclusivity in 2028 and decreased his out-year EPS estimates by over $1.00 due to yesterday's news. However, although near-term sentiment is dampened, he still sees a long-term opportunity, said Phipps, who keeps an Outperform rating on Bristol-Myers shares.
07/17/19
MZHO
07/17/19
NO CHANGE
Target $103
MZHO
Buy
Amgen seen by Mizuho as 'most likely' buyer of Celgene's Otezla
In the wake of the recent announcement that Bristol-Myers (BMY) plans to divest Otezla as part of its deal to acquire Celgene (CELG), Mizuho analyst Salim Syed said he has received questions on who could be a realistic buyer. He believes the "most likely" buyer would be Amgen (AMGN), followed by Johnson & Johnson (JNJ), which he would label as a "likely" buyer. Syed identifies the "less likely, but possible" buyers as Eli Lilly (LLY) and Regeneron (REGN). The analyst, who said Otezla is worth anywhere from $5B-$10B depending on the view of sales and synergy potential, keeps a Buy rating and $103 price target on Celgene shares.

TODAY'S FREE FLY STORIES

SNV

Synovus

$36.17

-1.075 (-2.89%)

05:31
09/20/19
09/20
05:31
09/20/19
05:31
Downgrade
Synovus rating change  »

Synovus downgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 13

    Nov

W

Wayfair

$128.67

-3.065 (-2.33%)

05:29
09/20/19
09/20
05:29
09/20/19
05:29
Initiation
Wayfair initiated  »

Wayfair initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XYL

Xylem

$77.99

-0.41 (-0.52%)

05:29
09/20/19
09/20
05:29
09/20/19
05:29
Initiation
Xylem initiated  »

Xylem initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Sep

  • 31

    Oct

PRDSY

Prada

$0.00

(0.00%)

05:28
09/20/19
09/20
05:28
09/20/19
05:28
Downgrade
Prada rating change  »

Prada downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BURBY

Burberry

$0.00

(0.00%)

05:27
09/20/19
09/20
05:27
09/20/19
05:27
Upgrade
Burberry rating change  »

Burberry upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JSAIY

J Sainsbury

$0.00

(0.00%)

05:26
09/20/19
09/20
05:26
09/20/19
05:26
Upgrade
J Sainsbury rating change  »

J Sainsbury upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$10.45

0.095 (0.92%)

05:25
09/20/19
09/20
05:25
09/20/19
05:25
Initiation
Freeport McMoRan initiated  »

Freeport McMoRan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Sep

ANFGY

Antofagasta

$0.00

(0.00%)

05:23
09/20/19
09/20
05:23
09/20/19
05:23
Downgrade
Antofagasta rating change  »

Antofagasta downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRC

AtriCure

$26.02

0.22 (0.85%)

05:21
09/20/19
09/20
05:21
09/20/19
05:21
Recommendations
AtriCure analyst commentary  »

AtriCure one of the most…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STIM

Neuronetics

$10.50

-0.54 (-4.89%)

05:19
09/20/19
09/20
05:19
09/20/19
05:19
Recommendations
Neuronetics analyst commentary  »

Piper calls Neuronetics a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FGEN

FibroGen

$39.69

-1.3 (-3.17%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

05:16
09/20/19
09/20
05:16
09/20/19
05:16
Hot Stocks
FibroGen, Astellas Pharma announce Japanese approval of Evrenzo »

FibroGen (FGEN) and…

FGEN

FibroGen

$39.69

-1.3 (-3.17%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

VOPKY

Koninklijke Vopak

$0.00

(0.00%)

05:16
09/20/19
09/20
05:16
09/20/19
05:16
Upgrade
Koninklijke Vopak rating change  »

Koninklijke Vopak…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBTYA

Liberty Global

$27.09

-0.25 (-0.91%)

05:12
09/20/19
09/20
05:12
09/20/19
05:12
Downgrade
Liberty Global rating change  »

Liberty Global downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 07

    Nov

HRI

Herc Holdings

$45.32

-1.615 (-3.44%)

, URI

United Rentals

$125.06

0.415 (0.33%)

05:06
09/20/19
09/20
05:06
09/20/19
05:06
Upgrade
Herc Holdings, United Rentals rating change  »

Herc Holdings upgraded to…

HRI

Herc Holdings

$45.32

-1.615 (-3.44%)

URI

United Rentals

$125.06

0.415 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

URI

United Rentals

$125.06

0.415 (0.33%)

05:03
09/20/19
09/20
05:03
09/20/19
05:03
Upgrade
United Rentals rating change  »

United Rentals upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

SUZ

Suzano

$15.97

-0.43 (-2.62%)

04:59
09/20/19
09/20
04:59
09/20/19
04:59
Downgrade
Suzano rating change  »

Suzano downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$133.76

3.97 (3.06%)

, CMCSA

Comcast

$46.68

-0.25 (-0.53%)

04:56
09/20/19
09/20
04:56
09/20/19
04:56
Initiation
Pivotal starts 'dramatically overvalued' Roku with Sell rating, $60 target »

Pivotal Research analyst…

ROKU

Roku

$133.76

3.97 (3.06%)

CMCSA

Comcast

$46.68

-0.25 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 27

    Oct

FTCH

Farfetch

$8.91

-0.42 (-4.50%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Cowen retail/luxury analyst to hold an analyst/industry conference call »

Retail & Luxury Goods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FB

Facebook

$190.15

1.96 (1.04%)

, SNAP

Snap

$16.87

-0.04 (-0.24%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
FBN Securities Tech/Internet analyst to hold a group luncheon »

technology and Internet…

FB

Facebook

$190.15

1.96 (1.04%)

SNAP

Snap

$16.87

-0.04 (-0.24%)

TWTR

Twitter

$42.94

-0.29 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

TRGP

Targa Resources

$40.89

-0.725 (-1.74%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Targa Resources management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

IRM

Iron Mountain

$32.15

-0.02 (-0.06%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Iron Mountain management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

LGND

Ligand

$104.62

5.37 (5.41%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Ligand management to meet with Craig-Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 02

    Oct

  • 13

    Nov

RDFN

Redfin

$17.19

-0.62 (-3.48%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Redfin management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

EXPI

eXp World Holdings

$8.45

0.33 (4.06%)

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
eXp World Holdings management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 07

    Oct

  • 08

    Oct

  • 13

    Nov

04:55
09/20/19
09/20
04:55
09/20/19
04:55
Conference/Events
Citigroup to hold a conference »

Growth Conference 2019…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.